Ron Lanton, Esq

Despite progress in reducing cancer mortality, more work is needed to improve patient outcomes in this disease state.

CRISPR technology may eventually hit the specialty landscape with promising treatments for HIV and cancer.

Telemedicine is becoming increasingly integrated into the operations of health care providers, but numerous questions linger.

Policy makers are working to address the needs of patients with Alzheimer's disease.

Landmark generic labeling rulings may foreshadow the issues that lie ahead when biosimilars enter the US market.

Pharmacists need to be aware of the medication and policy trends governing the use of early-stage drugs that have not been approved by the FDA.

Cost containment and formulary management policies can have a major effect on the ways in which specialty pharmacists provide services to patients.